Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors), mTORC1 inhibitors(Mammalian target of Rapamycin (mTORC1) inhibitors), mTORC2 inhibitors(mTOR Complex 2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 29 Dec 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 29 Dec 2021 | |
Hormone receptor positive HER2 negative breast cancer | IND Approval | CN | 08 Jan 2024 | |
Hormone receptor positive HER2 negative breast cancer | IND Approval | CN | 08 Jan 2024 |